Delgado, Silvia R.
Faissner, Simon
Linker, Ralf A.
Rammohan, Kottil http://orcid.org/0000-0003-2467-4280
Funding for this research was provided by:
Novartis AG
Article History
Received: 23 May 2023
Revised: 13 September 2023
Accepted: 14 September 2023
First Online: 31 October 2023
Declarations
:
: SRD has received research grant funding (clinical trials) from EMD Serono and Novartis. SF has received speaker’s and/or scientific board honoraria and/or congress travel support from Academy 2, Biogen, BMS, Celgene, Genesis Pharma, Janssen, Merck, Novartis and Roche and grant support from DMSG, Lead Discovery Center GmbH, Novartis, Ruhr-University Bochum and Stiftung für therapeutische Forschung; none related to this manuscript. RAL has received speaker’s and/or scientific board honoraria from Biogen, BMS, Celgene, Janssen, Novartis and Roche and grant support from Biogen and Novartis; none related to this manuscript. KR has received honoraria for participation in advisory boards or serving as consultant from Alexion Pharmaceuticals, Biogen, EMD Serono, Genentech, Horizon, Novartis and TG Therapeutics. KR has served as the site PI or co-investigator for grants received to his institution from Alexion, EMD Serono, Genentech, Genzyme and TG Therapeutics.